Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Release
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Release
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Study Suggests New Strategy to Treat Advanced Prostate Cancer
Disease Discoveries

Study Suggests New Strategy to Treat Advanced Prostate Cancer

By Anna WilliamsJan 23, 2019
Share
Facebook Twitter Email
Jindan Yu, MD, PhD, professor of Medicine in the Division of Hematology and Oncology and of Biochemistry and Molecular Genetics, and co-leader of the Translational Bridge Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, was the principal investigator of the study.

A Northwestern Medicine study has provided new insights into a signaling pathway underlying metastatic prostate cancer and suggests that combining a drug called galunisertib with established therapy may improve treatment response and slow cancer growth.

The study, published in the Journal of Clinical Investigation, was led by Jindan Yu, MD, PhD, professor of Medicine in the Division of Hematology and Oncology and of Biochemistry and Molecular Genetics.

Prostate cancer is the third-leading cause of cancer-related death among men in the U.S. Although localized prostate cancer is often successfully treated, there is no cure for metastatic prostate cancer, which remains a fatal disease.

Typically, advanced prostate cancers are first treated with hormone therapy, but most eventually become resistant to the treatment — a stage referred to as metastatic castration-resistant prostate cancer. The arrival of next-generation drugs such as enzalutamide have helped prolong patient survival, but most cancers soon develop resistance to these therapies, as well.

“There are about 30,000 deaths from prostate cancer every year, with a vast majority of lethality caused by metastatic castration-resistant prostate cancer. There is an urgent clinical need to prevent or overcome enzalutamide resistance,” explained Yu, also co-leader of the Translational Bridge Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Recent research has shown that castration-resistant prostate cancers develop resistance to enzalutamide through a mechanism known as lineage plasticity. Lineage plasticity allows prostate cancer cells to shift their phenotype from luminal epithelial cells to basal-like cells, which no longer depend on the target of hormone therapy, and therefore evade those treatments.

“There is an urgent clinical need to prevent or overcome enzalutamide resistance.”

In the current study, the Yu Laboratory demonstrated that a transcription factor called FOXA1 is an important regulator of lineage plasticity. They also showed that loss of the FOXA1 gene — one of the most frequently mutated genes in prostate cancers — significantly increased TGF-beta signaling, a pathway linked to cancer metastasis. The study’s findings confirm what has been a strong interest in the field to therapeutically target the TGF-beta pathway in advanced cancer.

Furthermore, the scientists demonstrated that a drug in clinical development called galunisertib — an inhibitor of the TGF-beta pathway — sensitized prostate cancer cells to enzalutamide. When used together, the two drugs synergistically inhibited cancer growth both in vitro and in a mouse model of castration-resistant prostate cancer.

“Our study suggests combinatorial use of enzalutamide and galunisertib in metastatic castration-resistant prostate cancer,” Yu said.

Northwestern is now participating in a multi-institutional clinical trial to evaluate the benefit of the drug combination in castration-resistant prostate cancer, compared to enzalutamide alone. Maha Hussain, MD, the Genevieve Teuton Professor of Medicine in the Division of Hematology and Oncology and deputy director of the Lurie Cancer Center, and Alicia Morgans, MD, MPH, associate professor of Medicine in the Division of Hematology and Oncology, are leading the clinical trial at Northwestern. Clinical samples will also be collected to determine whether FOXA1 and TGF-beta levels help predict patients’ response to the combinatorial treatment, Yu noted.

Bing Song, PhD, a postdoctoral fellow in Yu’s laboratory, was the first author of the study.

Read more:

  • New Understanding of Enzyme’s Role in Prostate Cancer
  • Men With Aggressive Prostate Cancer May Get New Powerful Drug Option
  • New Therapeutic Target Identified in Prostate Cancer

The study was supported in part by Northwestern’s National Cancer Institute-funded Prostate Cancer SPORE P50CA180995, National Institutes of Health grant R01CA172384 and R50CA211271, and Prostate Cancer Foundation grant 2017CHAL2008.

Biochemistry Cancer Research Women in Medicine
Share. Facebook Twitter Email

Related Posts

Changes in Medical School Leadership

Jan 26, 2023

Shortage of Mental Health Professionals Linked to Increase in Youth Suicides

Jan 25, 2023

Understanding How Childhood Brain Tumors Develop

Jan 23, 2023

Comments are closed.

Latest News

Changes in Medical School Leadership

Jan 26, 2023

Shortage of Mental Health Professionals Linked to Increase in Youth Suicides

Jan 25, 2023

Northwestern Medicine Scholars Program Inspires a New Generation of Physicians and Scientists 

Jan 24, 2023

Understanding How Childhood Brain Tumors Develop

Jan 23, 2023

Medical School Establishes New Center for Psychiatric Neuroscience

Jan 19, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
Feinberg_In_Vivo_20221209_tcrawford-24
Feinberg_In_Vivo_20221209_tcrawford-16
Feinberg_In_Vivo_20221209_tcrawford-14
Feinberg_In_Vivo_20221209_tcrawford-5
Feinberg_In_Vivo_20221209_tcrawford-6
Feinberg_In_Vivo_20221209_tcrawford-10
Feinberg_In_Vivo_20221209_tcrawford-8
Feinberg_In_Vivo_20221209_tcrawford-18
Feinberg_In_Vivo_20221209_tcrawford
Feinberg_In_Vivo_20221209_tcrawford-23
Feinberg_In_Vivo_20221209_tcrawford-25
Feinberg_In_Vivo_20221209_tcrawford-26

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.